these injuries. HS differ from normal skin and normal scars by exhibiting increased vascularization, increased fibroblast cell density, and a thickened epidermal cell layer [2] . During formation of HS, collagen accumulates to levels far in excess of that needed to replace the original volume oflost dermis. Once formed, the fate of HS is unpredictable; there may be partial or complete resolution, or the HS may remain permanently [3] . This complication is especially severe in children and is a majar cause of functional, cosmetic, and psychological morbidity [4, 5] . There is currently no clearly unifying theory to explain the pathogenesis of HS. Investigators have, however, identified the collagen nodule as the structural unit ofHS [6] . The nodule contains a high density of fibroblasts and unidirectional collagen fibrils. Microvessels encircle the main body of the nodule as a net with only a few vessels appearing within it. No such nodules are found in mature scar.
Our ability to control HS formation is limited, and -It is currently the most debilitating long-
,and at present, there is no routinely effective form oftherapy. In this study, we investigated the potential use of antibody-targeted photolysis (ATPL) in treating hypertrophic scars. An immunoconjugate consisting of a photosensitizer (Sn-chlorin e6) linked to a monoclonal antibody that binds to human myofibroblasts (PR2D3) was prepared, which in response to photoactivation produces singlet oxygen in clase proximity to the target cell surface. The model used for these studies consisted of l-mm3 human hypertrophic scar tissue implants in athymic mice. These implants increase approximately 20-fold in volume ayer a period of 15 days. Four days alter implantation immunoconjugate was injected directly into scar implants and alIowed to diffuse throughout for 24 hr before implants were ilIuminated with laser light at 630 nm (120 J/cm2) . ATPL treatment caused a significant remay be treated by duction in total growth compared to the untreated However controls (P < 0.05). No effect was observed when an bination therapy is usually irrelevant conjugate (anti-Pseudomonas aeruginosa) sion therapy is widely used with HS. Although the prewas used. Histological examination of the ATPL-cise mechanism ofthe compressive action is not known, treated implants 24 hr post-ATPL revealed the pres-it appears to be related to a combination offactors that ence of a large number of lipid droplets indicative of result in fibroblast degeneration and/or an alteration massive celI damage and infiltration by mononuclear ofthe collagen anabolism/catabolism ratio favoring cacelIs and neutrophils.
~ 1996 Academic Press, Inc. tabolism [7] . A majar drawback of compression therapy is that pressure must be maintained day and night for a minimum of 4 to 6 months [8] . The therapeutic effect of the application of various gel sheets in treating HS .has recently drawn considerable attention [9] . It has ..As a result of. advances In ~he care of th~ acutely been ostulated that the skin surface coverage of these I~Jured bum patIent, more patIents now routInely sur-gels kcreases the skin temperature which increases VIve to face the long-term consequences of moderate to th t f 11 t.. A possible altemative approach for treating HS involves targeting and destroying fibroblasts, the collagen-producing cells in HS. Using specific antibodies coupled with cytotoxic agents, one can selectively target these cells and hopefully reduce or prevent the formation of these scars while minimizing side effects and damage to surrounding tissue. Antibody-targeted photolysis (ATPL) is a technique which uses an immunoconjugate consisting of a photosensitizer covalently linked to a specific antibody. The cytotoxic effect is based upon the photosensitizer's ability to selectively absorb light at a specific wavelength and to initiate a chain of photochemical reactions that culminate in the production ofphototoxins such as singlet oxygen. Antibody-mediated localization ofthe photosensitizer limits the production of cytotoxins to the irnmediate vicinity of the targeted cell. By confining the illumination to the scar region, the cell killing can be limited to the target fibroblast population, while sparing other cell types within the scar and nontarget fibrobl.asts residing in other tissues.
In this study, we used a model of human HS tissue implanted subcutaneously in athymic mice [13] [14] [15] [16] . To test the potential of ATPL for treating HS, antifibroblast immunoconjugates were injected percutaneously into the implants and, following irradiation, scar growth was monitored for 21 days. The results clearly indicate that ATPL treatment was able to effectively limit HS growth when compared tocontrol treatments.
MATERIALS AND METHODS
Materials. PR2D3 is a monoclonal antibody (MAb) that was originally raised against a crude homogenate ofhuman colorectal mucosa and found to bind human smooth muscle cells in culture and stain myofibroblasts in tissue sections ofgut mucosa {17]. This antibody was produced from a mouse hybridoma cellline kindly supplied by Walter Bodmer (Director's Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London). HS tissue was obtaitled from three donors for this study. Athymic mice were obtained from Charles River Breeding Company (Wilmington, MA) and maintained in accordance with National Research Council Guidelines. Conjugation reagents included chlorin e6 (Porphrin Products. Logan, UT), ethylenediamine and sodium periodate (Sigma Chemiéal Company, Sto Louis, MO), 1,3-dicyclohexylcarbodiimide (DCC) (Aldrich Chemical Company, Milwaukee, WI), stannous chloride (MCB Manufacturing Chemists, Cincinnati, OH), and triethanolamipe (Fisher Scientific Company, Fair Lawn, NJ) Immunoconjugate synthesis. Immnnoconjugates were prepared by site-selective covalent addition oftin-chlorin e6 (SnCe6) groups' (with triethanolamine as axial ligands of the tin) to the oligosaccharide moiety on the Fc porlion of the MAb as described previously [18] . Briefiy, ethylenediamine is first coupled to chlorin e6 using the coupling agent DCC. Tin is then added using stannous chloride at 80°C, and axialligands are added by incubation with triethanolamine. Activated aldehyde groups on the MAb carbohydrate, introduced by mild periodate oxidation, react with the monoethylenediamine function on the derivatized SnCe6. The resulting Schiffs base is reduced with NaBHaCN to yield a stable amide linkage and the product is purified on a C18 reverse phase chromatography column (EM Science, Gibbstown, NJ). HPLC analysis of the immunoconjugate revealed a single peak with an elution pattern similar to that ofthe unconjugated MAb. Immunoconjugates which were used in this study were shown to contain an average ratio of photosensitizer to MAb of 1.3 based on the absorbances at 410 nm for SnCe6 and 280 nm for the MAb. This conjugate has previously been shown to kill fibroblasts but not keratinocytes cultured in collagen lattices [19] .
Tissue preparation. The HS tissue was harvested in the operating room after Operand iodine preparation solution (General Medical Corp., Prichard, WV) was applied to the skin. Tissue from three different donors were used in this study. The tissue was placed between two sterile gauze sponges soaked in normal saline and was kept at 4°C until it was transferred to a sterile dish containing Dulbecco's modified essential medium (Gibco BRL, Grand Island, NY) with 10% fetal calf serum (JRH Biosciences, Lenexa, KS) and 100 U/mI penicillin-streptomycin (JRH Biosciences, Lenexa, KS). Pieces were defatted and deepithelialized using a 15-0 scalpel and fine straight scissors. The remaining tissue (dermis) was minced into small (10 X 10 X 5-mm) blocks with a fresh 15-0 scalpel and washed three times with phosphate-bufrered saline (PBS), pH 7.4. After washing, the samples were further minced into 1 X 1 X 1-mm cubes (measured using a metric-ruled scalpel handle) and prepared for implantation into athymic mice. Processing oftissue was performed in a laminar flow hood at room temperature and implantation occurred within 4 hr after harvesting.
Athymic mouse hypertrophic scar modelo HS tissue was implanted into athymic mice using techniques previously described by others [13] [14] [15] [16] . Briefly, under sterile conditions, bilateral, linear, suprascapular incisions were made on the dorsum of the mice. The incisions were oriented transversely and were fuII thickness in depth. Curved microforceps were then introduced subdermally in the caudal direction to develop a pocket for the donor tissue. HS tissue pieces were blotted dry and placed in these pockets. The incisions were closed using two interrupted 5-0 chromic sutures. Each animal received two implants, one on each shoulder. A total of 40 animals were implanted with HS tissue using the tissue from three donors.
In vivo ATPL treatment. Four days after implantation, animals were lightly anesthetized with ether and the immunoconjugate was directly injected into each implanto Each implant received 200 JlI of an immunoconjugate solution in PBS, pH 7.4. Conjugate concentration was varied from 200 to 1000 nM. Twenty hours after receiving conjugate, one implant on each animal was shielded with a black cloth (dark control) while the other was irradiated (see Fig. 1 ) with continuous exposure to 100 mW/cm2 flux from a Kiton-red dye laser (Coherent, Palo Alto, CA). The animals were exposed to a surface fluence of 120 J/cm2, corresponding to an exposure of 80 J/cm2 across the skin thickness ofthe mouse [20] . Implant volumes were assessed at intervals of 3 days for up to 3 weeks using the method previously described by Waki et al. [16] . Briefly, calipers were used to measure the two-dimensional area (DI X D2) and thickness (D3) of the implants. These measurements were easily performed because the implants were clearly visible through the translucent skin of the animals. Since the implants appeared elliptical, volumes were calculated using the formula for an ellipsoid (11"/6 X DI X D2 X D3). To measure D3, the skin containing the implant was gently retracted (easily performed in this loose-skinned animal) so as to permit the calipers to completely surround the implanto In none of our animals were the implants adherent to the dorsal skeletal muscle fascia. The skin thickness was subtracted from the thickness measurement to yield the D3 value. Implant volumes were measured independently by the first two authors, and the error in the calculated volumes between investigators was less than 5%. Data were analyzed using ANOVA to determine statistical significance between the mean voltimes of the ATPL:.treated, untreated, and dark control implants at various time points after treatment.
Other control experiments were conducted using two animals in each category. As with the treatment group, each animal received two implants. One implant served as an untreated control, receiving no injection and no light. The other implant served as a treatment control, receiving 200 JlI of one ofthe following: (1) 1000 nM PR2D3, Incident Light "'1" Dark Cloth FIG. 1. Schematic diagram of ATPL in athymic mouse HS implant modelo Deepithelialized HS tissue was cut into l-mm3 pieces and implanted subcutaneously in the shoulder of nude mice. Each animal received two implants. After allowing the implants to grow for 4 days, immunoconjugate was injected locally. This conjugate binds to cells within the implant (right inset), and after 24 hr, one implant Bite was exposed to 120 J/cm2 of incident light at 630 nm while the other Bite was covered by a dark cloth to serve as a dark control. not statistically significant. However, a significant inhibition of growth occurred in implants receiving 1000 nM conjugate plus light irradiation. In the latter case, the volumes ofthe ATPL-treated implants were statisno light; (2) 1000 nM PR2D3 + light; (3) 1300 nM SnCe6, no light; (4) 1300 nM SnCe6 + light; (5) 1000 nM anti-Pseudomonas conjugate (used as a nonspecific conjugate), no light; and (6) 1000 nM antiPseudomonas MAb conjugate + light.
Histology. Histological analysis of the implants was also performed. At 24 hr, 48 hr, and seven days post-laser treatment, the animals were anesthetized with intraperitoneal chloral hydrate (200 JLI of 4 mg/100 mI) and skin implants were excised and immediately fixed in 10% formalin. The samples were sectioned and processed with hematoxylin-eosin (H & E) stain for viewing under the light microscope.
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RESULTS
In VivoATPL
HS implanted into athymic mice were assessed every 3 days for volumetric growth. Untreated implants exhibited continued growth for about 2-3 weeks, followed by a phase in which the implant volume subsided (Fig.  2 ). This growth pattern is similar to observations made by other investigators [14, 16] .
A total of 12 animals, each receiving two implants, were used in an initial study to determine the effect of conjugate concentration on implant growth. Animals were injected with 200 JLl of a200 nM, 500 nM, or 1000 nM immunoconjugate solution in both implants. In each animal, one implant Bite received a light clase of 120 J/cm2 while the other implant was shielded from light and served as a dark control. The effect of ATPL on implant growth is shown in Fig. 2 . Implants receiving 200 nM PR2D3 conjugate plus light displayed growth similar to that ofthe untreated and darkcontrol (i.e., given immunoconjugate, but no light) implants. Some inhibition was observed at 500 nM, but it was Conjugate concentrations tested were 200 nM (n = 4), 500 nM (n = 4), and 1000 nM (n = 4). The two.dimensional area and thickness of the implants were measured and volumes were calculated assuming an ellipsoid shape. Implant volume (mean :!: SD) versus time is shown for untreated implants (n = 12), ATPL-treated implants (implant site exposed to 120 J/cm2 oflight at 630 nm), and pooled dark controls (conjugate concentration had no effect on implant growth for these controls). The reduction in HS implant growth was significant with a conjugate concentration of 1000 nM (*P < 0.05).
~2 0 JOURNAL OF SURGICAL RESEARCH: VOL. 62, NO. 1, APRIL 1996 20 brane lipids frorn lysed cells. No vacuoles were observed in irnplants treated with unconjugated photosensitizer followed by laser irradiation (not shown), indicating that their forrnation was not due to thermolysis or nonspecific photolysis. ATPL-treated irnplants algo exhibited an infiltrate of inflarnrnatory cells consisting of predorninantly rnonocytes and rnacrophages (~80%), with Borne neutrophils present as well (~20%). The change in implant volume after treatment (Day 6 to Day 17) is compared for ATPL-treated and dark control implants using tissue from three different donors (n = 7 for donar 1, n = 4 for donar 2, and n = 4 for donar 3). Other controls included untreated implants (n = 12) as well as implants receiving 200 JLI of 1000 nM PR2D3 alone (n = 2), 1000 nM PR2D3 + light (n = 2), 1300 nM photosensitizer (PS) alone (n = 2), 1300 nM PS + light (n = 2), 1000 nM nonspecific (NS) anti-Pseudomonas MAb conjugate alone (n = 2), or 1000 nM nonspecific conjugate + light (n = 2).
tically lower (P < 0.05) than the volumes of the untreated or dark control implants from Day 9 to Day 21 postimplantation.
A surnmary of the effect of ATPL on implant growth using the tissue from three donors is shown in Fig. 3 . A total of 30 implants in 15 animals received 200 J.tl of a 1000 nM immunoconjugat~ splution (treatment group). Additional experiments included untreated (no injection, no light) implants as well as implants treated with unconjugated antibody (PR2D3); unconjugated 'photosensitizer (PS), and nonspecific (anti-Pseudomonas MAb) conjugate. Only those implants that received both the specific immunoconjugate and light showed an inhibition of growth. '
Histology
The most striking histological difference between ATPL-treated and dark control implants is the appearance of abundant "vacuoles" (Fig. 4) . Vac.uoles appear within 24 hr of ATPL treatment and by Day 7 are found throughout the implanto Histology of implants retrieved 48 hr posttreatment was found to be similar to that of the 24 hr posttreatment (not shown). These vacuoles are histologically similar to lipid droplets that forro during cell necrosis (sometimes called lipid degeneration) and presumably arise by coalescence of memWe have demonstrated retardation of the growth of HS implants in the athymic mouse using ATPL. This model is the closest approximation to human HS and keloids in which to test therapeutic strategies for the control of aberrant scar growth [13] [14] [15] [16] . The benefits of the system are that the scars grow in volume while maintaining their histological appearance, cellularity, and glycosaminoglycan distribution without being rejected by a cellular immune response. Implant growth can been attributed, at least in part, to an increase in collagen mass [14, 16] , and pharmacological agents that inhibit collagen synthesis have been used to inhibit this growth. The main disadvantage ofthis model is that the scars naturally resorb approximately 3 weeks after implantation. Possible explanations for this resorption may involve rejection of the HS implants, production of collagenase by the mouse cells to degrade the HS tissue, or disappearance of the stimulus for excessive collagen synthesis by the HS fibroblast.
The athymic mouse implant model has previously been used to test various pharmacological agents such as triamcinolone, acetylcysteine, colchicine, and penicillamine [16] . ATPL resulted in an approximately 81% inhibition of implant growth compared to 72% for triamcinolone, 43% for acetylcysteine, 54% for colchicine, and 20%for penicillamine. In addition, ATPL has the advantage of minimizing systemic toxic reactions by exposing only the implants to the laser irradiation. The high specificity of ATPL for the target cell population was clearly shown by control experiments which were performed using PR2D3, photosensitizer, and nonspecific conjugate, with and without light exposure. Since no differences were observed in the growth curves in these controls compared to untreated implants, we can conclude that both aspects of ATPL (cell targeting via antibody/antigen binding and light-induced generation of phototoxins) were necessary to inhibit implant growth. This is the first demonstration ofusing ATPL to control HS growth in an animal modelo
The host response to the ATPL-treated scar implants was characterized by the presente of inflammatory cells within the implants. These inflammatory cells were predominantly (roughly 80%) monocytes and macrophages, with the remaining being neutrophils. In addition, an increasing number ofvacuoles was observed as a function of time after treatment, which is consistent with a necrotic reaction within the implanto Consequently, the necrotic reaction caused by ATPL may play an important role in the observed implant growth inhibition.
Although the PR2D3 MAb was initially reported to bind myofibroblasts in tissue sections of human gut mucosa [17], we have recently found that the PR2D3-PS conjugate, but not the anti-Pseudomonas-PS conjugate, efficiently kills fibroblasts cultured in fibroblast-populated collagen lattices [19] . In addition, we found that the PR2D3 conjugate does not kill cultured keratinocytes, which supports the hypothesis that a prime target for ATPL was the fibroblasts in the scar implanto Examinations of histological sections reveal that 100% killing offibroblasts was not achieved at the light dose and immunoconjugate concentrations used in this study. These doses have be en previously shown to kill approximately 105 fibroblasts in a fibroblast-populated collagen lattice model [19] . This is of the same arder of magnitude as the number of fibroblasts in the 1.0-mm-thick implants at the time ofATPL treatment (estimated by counting the number of fibroblasts in 5-ji,m-thick histological sections of several implants, and assuming that the fibroblasts are uniformly distributed in the implant). Undoubtedly, there is Borne loss of the injected immunoconjugate ayer the 24-hr period prior to laser treatment. In addition, scavenging of singlet oxygen by endogenous proteins in the scar mass could potentially decrease the net cytotoxic yield. Future work to investigate immunoconjugate transport is warranted in arder to detennine the optimum conjugate concentration, light dose, and irradiation time after conjugate injection for inhibiting scar growth.
Although the specificmechanism of action of ATPL on implant growth needs further clarification, the results presented in this paper demonstrate the potential of this approach in the treatment andlor prevention of HS. Since a suitable animal model of HS formation does not exist, the true test for the technique of ATPL would be in treating HS in a clinical trial in burn patients. This would most likely involve the local injection of a surgically debulked HS with immunoconjugate, followed by laser irradiation of the lesion after 24 hr with the intention of eradicating those fibroblasts at the borders of the lesion that could be responsible for the overproduction of extracellular matrix.
The lack of a basic understanding of the mechanism ofHS formation has prevented the development
